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The renin-angiotensin system (RAS) was extensively investigated and character-
ized throughout the first half of the 20th century. However, its contribution to the 
maintenance of high blood (BP) in essential hypertension and to the development of 
hypertensive cardiac complications remained under debate until the advent of the 
first pharmacologic probes capable of blocking its actions, namely the angiotensin 
receptor blocker (ARB) saralasin and the angiotensin-converting enzyme inhibitor 
(ACEI) teprotide in the early 1970’s. Using these probes, we could demonstrate that 
even in normal-renin and low-renin hypertension, blockade of the RAS produced a 
fall in BP. And this fall was maximized if the patient had been previously submitted to 
sodium depletion by diuretics or low salt diet, which might produce only a small and 
possibly insignificant BP fall by itself, but rendered the hypertension RAS-dependent 
and far more responsive to RAS blockade.
In parallel, we had found that excess angiotensin II, either exogenous (in experi-
mental animals) or endogenous, in various clinical settings, could produce significant 
cardiac and renal tissue damage, because the vasculature of these organs is particularly 
sensitive to the constricting effects of angiotensin. In particularly, angiotensin excess 
was shown to produce widespread foci of necrosis and scarring of the myocardium, 
leading to replacement of myocardial tissue by fibrotic tissue, eventually progressing 
to ischemic cardiomyopathy and heart failure.
Early clinical trials found that treatment of heart failure with ACEIs or ARBs 
leads to significant hemodynamic improvement in terms of increased cardiac output, 
decreased peripheral arterial resistance, decreased heart rate, increased coronary 
blood flow and diminished myocardial oxygen consumption. Subsequent large rand-
omized long-term outcome trials with ACEIs or ARBs, such as the HOPE, EUROPA, 
LIFE, CHARM, etc., confirmed the functional and structural benefits of these 
therapeutic approaches and have now established treatment with an ACEI or ARB 
as mandatory therapy for patients with ischemic heart disease, as well as congestive 
or chronic heart failure.
It is also now universally accepted that initiation of RAS-suppressing therapy with 
an ACEI or ARB in patients with multiple cardiovascular risk factors, even not neces-
sary including hypertension, offers long-term protection from ischemic heart disease, 
diastolic and systolic cardiac dysfunction, arrhythmias, as well as protection from renal 
insufficiency, cerebrovascular accidents and new onset type 2 diabetes mellitus.
Drugs that inhibit the RAS now include, in addition to the ACEIs and ARBs, a 
new class, the direct renin inhibitors (DRIs), of which only aliskiren is commercially 
available to date. Several clinical trials have shown aliskiren to be equally effective to 
ACEIs and ARBs in terms of BP lowering, cardioprotection and nephroprotection.
A large body of literature has now reported additional benefits of ACEI+ARB 
combination in selected patients, i.e., those with resistant hypertension on multidrug 
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therapy and, in particular, those with progressive renal insuf-
ficiency and persistent proteinuria, with or without coexisting 
diabetes mellitus. All studies report better control of proteinu-
ria—a surrogate marker of severity of the nephropathy—al-
though success in terms of final outcomes, such as rate of 
progression to end-stage renal disease, cardiovascular events 
or overall morbidity and mortality, has not been consistent. 
Perhaps because of these mixed results, there has been no 
effort to proceed to a fixed combination of ACEI+ARB.
The advent of the novel class of DRIs presents a new pos-
sibility for dual blockade of the RAS. The pattern of changes 
in the various components of the RAS under direct inhibition 
of renin differs from that observed under chronic use of ACEI 
or ARB. Specifically, despite increase in renin concentration, 
the levels of plasma renin activity, angiotensin I, angiotensin 
II and aldosterone remain consistently suppressed, with 
no evidence of “escape”. Therefore, a dual blockade of the 
RAS with a DRI plus either ACEI or ARB would be more 
absolute. Early studies of such combinations have produced 
promising results in terms of improved markers of progres-
sion of renal disease and severity of heart failure, without 
significant adverse events. However, there are not yet large 
longitudinal clinical trials to establish the benefits of such 
combinations in terms of important change in final outcomes. 
Notwithstanding these considerations, there is now a large 
body of clinical evidence supporting the long-term benefits 
of suppressed RAS for the protection of structure and func-
tion of vital organs.
